UroGen Pharma Ltd. - Ordinary Shares (URGN)

The company is working on a treatment for non-muscle invasive bladder cancer.

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of phosphorus munitions. UNSC to convene tomorrow.

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share.

The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023.

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.